Gilead details its case for a new HIV flagship triple, with megablockbuster potential
Gilead $GILD laid out a detailed case for its HIV triple today, journeying to a scientific conference in Paris to present the data from a pair of Phase III studies that demonstrated the combo pill lined up quite nicely alongside GlaxoSmithKline’s dolutegravir.
Adding bictegravir to its backbone HIV drugs emtricitabine/tenofovir alafenamide (200/25mg) (FTC/TAF) produced similar high efficacy results with the GSK rival with a similar safety profile.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
